Furthermore, in a prospective case–control study, Mattsson and colleagues found the precision of plasma NFL in distinguishing AD patients from healthy controls was equivalent to well-known CSF AD biomarkers and substantially higher than plasma tau [6]. The gene discussed is MAPT; the disease is Alzheimer disease.